Archives of Medical Science最新文献

{"title":"TREM-1 inhibition or ondansetron administration ameliorates NLRP3 inflammasome and pyroptosis in traumatic brain injury-induced acute lung injury.","authors":"Fen Li, Na Qin, Yiqin Yu, Rui Dong, Xiaojie Li, Shenhai Gong, Zhenhua Zeng, Lin Huang, Hong Yang","doi":"10.5114/aoms/174264","DOIUrl":"https://doi.org/10.5114/aoms/174264","url":null,"abstract":"<p><strong>Introduction: </strong>Recently, NLR family pyrin domain containing 3 (NLRP3) and pyroptosis have been reported to be involved in traumatic brain injury-induced acute lung injury (TBI-ALI). Studies have shown that triggering receptor expressed on myeloid cells-1 (TREM-1) may be one of the upstream molecules regulating NLRP3/pyroptosis, and 5-hydroxytryptamine type 3-receptor (5-HT3R) antagonists can inhibit NLRP3/pyroptosis. However, the role of TRME-1 in TBI-ALI, the therapeutic effect of 5-HT3R inhibition on TBI-ALI and its mechanism are still unclear. Therefore, this study aimed to evaluate the protective effect of ondansetron, a 5-HT3 inhibitor, on TBI-ALI, and to explore whether the underlying mechanism is related to the regulation of TREM-1.</p><p><strong>Material and methods: </strong>A TBI-ALI rat model was constructed via lateral fluid percussion (LFP) brain injury, and either TREM-1 inhibitor (LP17) or ondansetron was administered as needed.</p><p><strong>Results: </strong>TBI induced NLRP3 inflammasome, pyroptosis, and TREM-1 activation in rat lung tissues in a time-dependent manner. Inhibition of TREM-1 activity attenuated TBI-ALI; this is evident from reduced pathological scores, wet/dry ratios, and bronchoalveolar lavage fluid protein levels and alleviated NLRP3 inflammasome/pyroptosis. In addition, ondansetron reduced NLRP3 inflammasome/pyroptosis and alleviated TBI-ALI. Moreover, ondansetron reduced TREM-1 activation in macrophages and lung tissue.</p><p><strong>Conclusions: </strong>Ondansetron alleviated TBI-ALI. In terms of mechanism, TREM-1 promotes TBI-ALI via the NLRP3-related pyroptosis pathway, and the protective effect of ondansetron on TBI-ALI may be related to the inhibition of TREM-1.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"984-996"},"PeriodicalIF":3.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexistence of adult-onset Still's disease and SAPHO syndrome.","authors":"Yunuo Wang, Haixu Jiang, Xinbo Yu, Qiuwei Peng, Zixiang Zheng, Yuanhao Wu, Chen Li","doi":"10.5114/aoms/189502","DOIUrl":"https://doi.org/10.5114/aoms/189502","url":null,"abstract":"","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"1053-1056"},"PeriodicalIF":3.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pepsinogen I, pepsinogen II, gastrin-17, and <i>Helicobacter pylori</i> serological biomarkers in the diagnosis of precursor lesions of gastric cancer.","authors":"Josefina Yoaly Sánchez-López, Luis Carlos Díaz-Herrera, Lourdes Del Carmen Rizo-de la Torre","doi":"10.5114/aoms/189971","DOIUrl":"https://doi.org/10.5114/aoms/189971","url":null,"abstract":"<p><strong>Introduction: </strong>Atrophic gastritis and intestinal metaplasia are precursor lesions of gastric cancer. The aim of this study was to determine the usefulness of the biomarkers pepsinogen I(PgI), pepsinogen II (PgII), gastrin-17, and <i>H. pylori</i> antibodies in the identification of precursor lesions.</p><p><strong>Methods: </strong>We studied 129 patients with gastric symptoms. The biomarker status was determined using GastroPanel by means of the ELISA-technique.</p><p><strong>Results: </strong>Biomarkers detected atrophy in 14% of the subjects, and 49.6% had positive antibodies for <i>H. pylori</i>. A PgI/PgII ratio < 3 was an important risk biomarker for precursor lesions in our population (OR = 9.171, 95% CI: 1.723-48.799, <i>p</i> = 0.009); however, biomarkers showed low accuracy with histopathological study.</p><p><strong>Conclusions: </strong>In the Western Mexican population, precursor lesions (AG, IM) are common in adults (45%) with dyspepsia but infrequent in children (8%). <i>H. pylori</i> infection was detected in 41.3% of adults and 16.0% of children. Of the studied biomarkers, a PgI/PgII ratio < 3 was an important risk factor for precursor lesions such as AG or IM in our population, with an OR of 9.171 (95% CI: 1.723-48.799, <i>p</i> = 0.009).</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"1016-1021"},"PeriodicalIF":3.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Delayed multiple arterial haemorrhage after pelvic fracture: report of a rare case.","authors":"Jiao Dai, Junhong He, Shan Gao, Feng Cao, Ying Ying","doi":"10.5114/aoms/188204","DOIUrl":"https://doi.org/10.5114/aoms/188204","url":null,"abstract":"","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 4","pages":"1374-1377"},"PeriodicalIF":3.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493062/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142516256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute renal failure caused by Sjögren's syndrome and rheumatoid arthritis overlap syndrome.","authors":"Lei Ran, Ya-Pu Zhang, Li Guo, Zhi-Min Wang, Jian-Min Zhang","doi":"10.5114/aoms/187780","DOIUrl":"https://doi.org/10.5114/aoms/187780","url":null,"abstract":"<p><strong>Introduction: </strong>Sjögren's syndrome (SS) and rheumatoid arthritis (RA) are two chronic autoimmune diseases. To date, there have been few reports on the overlap between SS and RA in China, especially regarding correlated acute renal failure cases.</p><p><strong>Methods: </strong>To provide a reference for our clinical peers, this article presents the case report of an elderly female patient who was diagnosed with acute renal failure caused by SS and RA overlap syndrome.</p><p><strong>Results: </strong>We also provide a relevant analysis of SS and RA overlap syndrome treatment.</p><p><strong>Conclusions: </strong>We also provide a relevant analysis of SS and RA overlap syndrome treatment.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"1034-1037"},"PeriodicalIF":3.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic value of circulatory growth factors to predict responsiveness to chemotherapy and remission status of patients with acute myeloid leukemia.","authors":"Mohammad Ahmad Bani-Ahmad, Duaa Ghanem","doi":"10.5114/aoms/185617","DOIUrl":"10.5114/aoms/185617","url":null,"abstract":"<p><strong>Introduction: </strong>Tumor neovascularization, an essential requirement for malignant disease progression and metastasis, depends on the dysregulation of pro-angiogenic and anti-angiogenic activities. This study aimed to investigate the utilization of circulatory angiopoietins (Ang-1 and Ang-2), vascular endothelial growth factor (VEGF-A and VEGF-C), and basic fibroblast growth factor (bFGF) as a prognostic tool for acute myeloid leukemia (AML).</p><p><strong>Material and methods: </strong>Twenty-four AML patients who were under chemotherapeutic intervention were included. Patients' relapse status, responsiveness to chemotherapy, and remission status were obtained from their medical profiles. For comparative purposes, fifteen healthy subjects were included. Serum levels of growth factors were measured.</p><p><strong>Results: </strong>As compared to control subjects, AML patients had significantly lower average levels of Ang-1 (170.8 ±12.7 versus 59.2 ±12.5 ng/ml) and VEGF-A (56.0 ±13.1 versus 98.6 ±11.9 ng/dl) that coincide with a higher average level of Ang-2 (18.5 ±4.1 ng/ml versus 7.5 ±0.8 ng/ml). Spearman's correlation analysis defined a significant association of sAng-1 and sAng-2 with patients' response to chemotherapy (ρ = 0.488) and remission status (ρ = 0.476), respectively. According to the receiver operating characteristic (ROC) curve, downregulation of Ang-1 has good predictivity for poor responsiveness to chemotherapy (AUC = 0.781, <i>p</i> < 0.05) while upregulation of sAng-2 has good predictivity for failed remission status (AUC = 0.779, <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>In the context of AML, dysregulated circulatory levels of Ang-1 and Ang-2 are suggested prognostic markers to provide useful predictivity of patients' adverse responsiveness to chemotherapy and remission status, respectively.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 6","pages":"1887-1893"},"PeriodicalIF":3.0,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microsatellite instability and somatic gene variant profile in solid organ tumors.","authors":"Ibrahim Halil Erdogdu, Seda Orenay-Boyacioglu, Olcay Boyacioglu, Nesibe Kahraman-Cetin, Habibe Guler, Merve Turan, Ibrahim Meteoglu","doi":"10.5114/aoms/185326","DOIUrl":"10.5114/aoms/185326","url":null,"abstract":"<p><strong>Introduction: </strong>Absence of mismatch repair (MMR) genes in tumor cells or errors in the replication repair process may lead to DNA-MMR deficiency and microsatellite instability (MSI) formation. Specific tumor environments where gene variations are observed are believed to be conducive to the formation of MSI. This study aimed to determine the MSI status, MMR protein expression, and somatic mutation profile in solid organ tumors.</p><p><strong>Material and methods: </strong>In this study, the records of 192 patients with solid organ tumors who were referred to the Molecular Pathology Laboratory between January 2018 and December 2022 were reviewed retrospectively. The MSI profiles of the patients were evaluated using real-time polymerase chain reaction (PCR) and immunohistochemical (IHC) methods. Somatic variations in the patients were detected using an NGS colon cancer panel.</p><p><strong>Results: </strong>In the IHC evaluation, 22 cases showed MMR-deficient (dMMR) or high MSI (MSI-H), and 170 cases showed MMR-proficient (pMMR) or microsatellite stable (MSS). Real-time PCR results on the 22 dMMR cases revealed that 11 cases had MSI-H and 11 cases had MSS status. Among the 170 cases with pMMR, 160 cases were found to have MSS status, while 10 cases had low MSI (MSI-L). NGS analysis revealed that the three most frequent pathogenic variants in all cases were <i>BLM</i> exon 7 <i>c.1544delA</i>, <i>MSH3</i> exon 7 <i>c.1148delA</i>, and <i>MLH3</i> exon 2 <i>c.1755delA</i>. MSI-H cancer patients had a higher variation burden compared to MSS cancer patients. The most frequently observed pathogenic variant in both MSI-H and MSS cancer patients was <i>BLM</i> exon 7 <i>c.1544delA</i>.</p><p><strong>Conclusions: </strong>Our study covers not only colorectal cancer patients but also other solid tumor types, providing the first data from the Turkish population on the MSI-H/dMMR status and somatic mutation profile in the presence of this condition.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 5","pages":"1672-1679"},"PeriodicalIF":3.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the effectiveness of the helmet interface using flow meters versus the mechanical ventilator for non-invasive ventilation in patients with coronavirus disease 2019. Controlled and randomized clinical trial.","authors":"Fernanda Dos Reis Ferreira, João Carlos Ferrari Correa, Eduardo Storopoli, Diego Restivo Faria, Karina Cassaro, Natália Feitosa da Hora, Raphael Ritti, Rafael Akira Becker, Simone Dal Corso, Ivan Peres Costa, Luciana Maria Malosá Sampaio","doi":"10.5114/aoms/183947","DOIUrl":"10.5114/aoms/183947","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to compare the effectiveness of two methods for non-invasive mechanical ventilation in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) - using a helmet interface with a flow meter and positive end-expiratory pressure valve versus a traditional mechanical ventilator.</p><p><strong>Material and methods: </strong>We conducted a single-center randomized clinical trial involving 100 adult SARS-CoV-2 patients in a specialized private hospital. Participants were randomly assigned to two groups: one using the helmet interface with a flow meter and positive end-expiratory pressure valve and the other employing conventional mechanical ventilation. Our study included participant selection, blood gas analysis, assessment of respiratory rate, peripheral oxygen saturation, modified Borg scale scores, and a visual analog scale.</p><p><strong>Results: </strong>The study showed no significant difference in intubation rates between the mechanical ventilation (54.3%) and helmet interface with flow meter and positive end-expiratory pressure valve (46.8%) groups (<i>p</i> = 0.37). Additionally, the helmet group had a shorter average duration of use (3.4 ±1.6 days) compared to the mechanical ventilation group (4.0 ±1.9 days). The helmet group also had a shorter average hospitalization duration (15.9 ±7.9 days) compared to the mechanical ventilation group (17.1 ±9.5 days).</p><p><strong>Conclusions: </strong>This single-center randomized clinical trial found no statistically significant differences between the two methods of non-invasive ventilation. Implications for clinical practice: using the helmet interface with the flow meter and positive end-expiratory pressure valve can simplify device installation, potentially reducing the need for intubation, making it a valuable tool for nurses and physiotherapists in daily clinical practice.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 5","pages":"1538-1546"},"PeriodicalIF":3.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incremental long-term benefit of drug therapies for chronic obstructive pulmonary disease in quality of life but not mortality: a network meta-analysis.","authors":"Qiong Pan, Jiongzhou Sun, Shiyuan Gao, Zian Liu, Yiwen Huang, Yixin Lian","doi":"10.5114/aoms/183025","DOIUrl":"10.5114/aoms/183025","url":null,"abstract":"<p><strong>Introduction: </strong>The latest evidence revealed that dupilumab, an interleukin-4 (IL-4) and interleukin-13 (IL-13) blocker, significantly reduces the exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The efficacy of dupilumab compared with conventional inhaled drugs remains incompletely determined. This study aimed to investigate the comparative efficacy of dupilumab and conventional inhaled drugs in patients with stable COPD.</p><p><strong>Material and methods: </strong>This study retrieved randomised clinical trials (RCTs) with follow-up ≥ 48 weeks on long-acting β-agonists (LABAs), long-acting muscarinic receptor antagonists (LAMAs), inhaled corticosteroids (ICSs), and dupilumab in the PubMed, EMBASE, and Cochrane Central Register of Controlled Trials databases. The information on eligible studies was extracted after the screening. The comparative efficacy of 4 drugs and their combinations in acute exacerbation and mortality was assessed using Bayesian network meta-analysis models.</p><p><strong>Results: </strong>This network meta-analysis identified 69 eligible RCTs on 7 classes of drug therapies after stepwise screening and included 125,331 COPD patients. Compared with placebo, the 7 drug interventions significantly reduced the risk of acute exacerbation, and the reduction degree increased with the incremental use of drug classes. ICS/LABA/LAMA/dupilumab was the most effective in decreasing exacerbation risk (OR = 0.561 [95% CI: 0.387-0.810]), followed by ICS/LABA/LAMA (OR = 0.717 [95% CI: 0.626-0.817]). The 7 drug therapies were not significantly associated with a lower risk of death compared to placebo. Nevertheless, ICS/LABA/LAMA/dupilumab is the most likely to be effective in decreasing mortality.</p><p><strong>Conclusions: </strong>The incremental use of combinations of conventional and novel drugs contributed to the long-term benefits in acute exacerbation but not death in COPD. The optimal drug combination in terms of acute COPD exacerbation was ICS/LABA/LAMA/dupilumab.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 5","pages":"1586-1596"},"PeriodicalIF":3.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11623174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142794415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) for poor prognosis after intravenous thrombolytic therapy for acute ischaemic stroke.","authors":"Yinglei Li, Lingyun Xi, Litao Li","doi":"10.5114/aoms/178013","DOIUrl":"10.5114/aoms/178013","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to examine the relationship between monocyte-to-high-density lipoprotein-cholesterol ratio (MHR) and poor short-term 3-month and long-term 6-month prognosis after intravenous thrombolysis in patients with acute ischaemic stroke.</p><p><strong>Material and methods: </strong>By retrospective analysis, 763 eligible patients with acute ischaemic stroke with intravenous thrombolysis were included in the study, and the general data and clinical laboratory examination results of the patients were collected. The relationship between MHR and poor prognosis at 3 and 6 months in patients with intravenous thrombolysis was derived by stepwise regression using the R language, followed by 1:1 propensity score matching to determine the MHR threshold and to investigate the relationship between high and low MHR values and poor prognosis.</p><p><strong>Results: </strong>MHR level was found to predict the prognosis of intravenous thrombolysis patients with acute ischaemic stroke, and it was an effective predictor of poor prognosis at 3 and 6 months after intravenous thrombolysis. MHR has a threshold of 0.584. High MHR levels were strongly associated with a poor 3-month prognosis of intravenous thrombolysis in patients with acute ischaemic stroke (OR = 5.657; 95% CI: 4.124-7.762; <i>p</i> < 0.001). High MHR level was closely associated with poor prognosis of acute ischaemic stroke patients with intravenous thrombolysis at 6 months (OR = 4.923; 95% CI: 3.603-6.726; <i>p</i> < 0.001).</p><p><strong>Conclusions: </strong>MHR level is a valid predictor for poor prognosis at 3-6 months after intravenous thrombolysis in patients in acute ischaemic stroke.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 6","pages":"1809-1821"},"PeriodicalIF":3.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11831341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}